Design Therapeutics, Inc. (DSGN): Price and Financial Metrics

Design Therapeutics, Inc. (DSGN): $12.94

0.99 (+8.28%)

POWR Rating

Component Grades













Add DSGN to Watchlist
Sign Up

Industry: Biotech



in industry

DSGN Stock Price Chart Interactive Chart >

Price chart for DSGN

DSGN Price/Volume Stats

Current price $12.94 52-week high $28.49
Prev. close $11.95 52-week low $9.61
Day low $11.68 Volume 120,400
Day high $13.19 Avg. volume 161,275
50-day MA $13.97 Dividend yield N/A
200-day MA $15.60 Market Cap 721.82M

Design Therapeutics, Inc. (DSGN) Company Bio

Design Therapeutics, Inc. develops therapies for the treatment of degenerative disorders caused by nucleotide repeat expansions. The company engages in the development of a program for the treatment of Friedreich's ataxia and degenerative diseases such as Fragile X syndrome and myotonic dystrophy. The company was incorporated in 2017 and is based in Carlsbad, California.

DSGN Latest News Stream

Event/Time News Detail
Loading, please wait...

DSGN Latest Social Stream

Loading social stream, please wait...

View Full DSGN Social Stream

Latest DSGN News From Around the Web

Below are the latest news stories about Design Therapeutics Inc that investors may wish to consider to help them evaluate DSGN as an investment opportunity.

Design Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference

CARLSBAD, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today reported that João Siffert, M.D., president and chief executive officer, and Sean Jeffries, Ph.D., chief operating officer, will participate in a fireside chat during the SVB Leerink 11th Annual Global Healthcare Conference on Thursday, February 17, 2022 at 11:20 a.m. ET. A live webcast will be available in the inves

Yahoo | February 10, 2022

Design Therapeutics names new medical chief

Design Therapeutics (DSGN) announced the appointment of Jae Kim, M.D., as the companys new Chief Medical Officer.Before joining Design (DSGN), Dr

Seeking Alpha | February 1, 2022

Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer

CARLSBAD, Calif., Feb. 01, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced that Jae Kim, M.D., FACC, has been appointed as chief medical officer. Dr. Kim will play a pivotal role in leading clinical strategy and development, including the company’s first clinical trial planned to begin in the first half of 2022. “I am thrilled to welcome Jae to Design, particularly as we prepare t

Yahoo | February 1, 2022

Design Therapeutics Shares Fall As Goldman Sachs Initiates With Sell Rating

Goldman Sachs initiated coverage of Design Therapeutics Inc (NASDAQ: DSGN ) with a Sell rating and a $10 price target. The analyst Madhu Kumar has caution about the Company''s lead indication of Friedreich ataxia. Natural history studies provide little support that differences in FXN levels will shift the FA disease course. At the same time, high-dose nicotinamide has already achieved clinically meaningful FXN induction with the minimal observed change in Full story available on

Benzinga | January 19, 2022

Design Therapeutics (NASDAQ:DSGN) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Yahoo | December 23, 2021

Read More 'DSGN' Stories Here

DSGN Price Returns

1-mo 2.62%
3-mo -4.36%
6-mo -27.22%
1-year -50.61%
3-year N/A
5-year N/A
YTD -39.56%
2021 N/A
2020 N/A
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 1.0351 seconds.